Category: Cancer (Oncology), HIC#14351
Title:
A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BEVACIZUMAB (NSC #704865, IND #7921) VERSUS THE NON-PLATINUM DOUBLET, TOPOTECAN PLUS PACLITAXEL, WITH AND WITHOUT NCI-SUPPLIED BEVACIZUMAB, IN STAGE IVB, RECURRENT OR PERSISTENT CARCINOMA OF THE CERVIX. GOG 240
Contact:Heather Lothamer
Phone:(434)243-0315
E-mail:hll5y@virginia.edu

UVa Health System, the Department of Obstetrics and Gynecology, the division of Gynecologic Oncology, seeks Women ages 18 and above with newly diagnosed stage IVB, recurrent or persistent cervical cancer for research study.

The purpose of the study is to compare the effectiveness, safety, and the impact on health related quality of life of cisplatin and paclitaxel, cisplatin and paclitaxel plus bevacizumab, paclitaxel and topotecan, as well as paclitaxel and topotecan plus bevacizumab. Thus, there are four drug combinations possible. The reason why other drugs and other drug combinations need to be studied is because many women who have not been cured of their cervical cancer have already received cisplatin as part of their original radiation therapy and the possibility of the relapsing cancer having become
resistant to cisplatin is of some concern. For this reason cisplatin is not being studied in two of the four possible treatment arms. Topotecan has been shown to have clinical benefit when combined with paclitaxel in one study and for this reason the combination of topotecan and paclitaxel was selected for the two treatment arms not containing cisplatin.

ยง No compensation is provided for this study.

Contact Information:
For more information please contact:
" Heather Lothamer, MSN
" 434-924-2745 or HLL5y@virginia.edu
" IRB-HSR #14351

Principal Investigator: Susan Modesitt, MD
Primary Investigator: Modesitt Susan, C
Department: Obstetrics & Gynecology
 Accepts adult enrollment :NO
Accepts minor enrollment :NO